COLL · Earnings event · Q2 2026 · archived
Collegium Pharmaceutical (COLL) Q2 2026 earnings — TrendMatrix coverage
Reported · EPS $1.92 vs estimate $1.77 (+8.8%) — classified BEAT.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
EPS beat/miss and revenue
| Metric | Estimate | Actual | Surprise |
|---|---|---|---|
| EPS (diluted) | $1.77 | $1.92 | +8.8% |
| Revenue (2026-06-30) | — | $199.9M | — |
Revenue source: xbrl.
Verdict reaction
How the verdict moved around this report
Before this report, TrendMatrix rated COLL Buy (Wait) at 6.5/10. After the Q2 2026 report, the verdict moved to Sell at 6.6/10.
Healthcare context
COLL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $875.1M
- P/E (fwd)
- 4.0
- P/E (ttm)
- 22.2
- 52-week range
- $25.47–$50.79
- Off 52-week high
- 44.4%
- RSI (14)
- 26
- Volume vs avg
- 1.09×
- Engine score
- 5.8/10
Live context at TrendMatrix’s latest engine read — updates after the report date; not frozen to it.